Comparison of stage III mucinous and serous ovarian cancer: a case-control study


Cuylan Z. F. , Karabuk E. , Oz M., Turan A. T. , Meydanli M. M. , TAŞKIN S., ...Daha Fazla

JOURNAL OF OVARIAN RESEARCH, cilt.11, 2018 (SCI İndekslerine Giren Dergi) identifier identifier identifier

Özet

Background: The purpose of this case-control study was to compare the prognoses of women with stage III mucinous ovarian carcinoma (MOC) who received maximal or optimal cytoreduction followed by paclitaxel plus carboplatin chemotherapy to those of women with stage III serous epithelial ovarian cancer (EOC) treated in the similar manner.